Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04305691 · ClinicalTrials.gov registry record · Phase 2
Trial of Ixazomib for Kaposi Sarcoma
A Phase 2 study of Kaposi Sarcoma and Skin, sponsored by AIDS Malignancy Consortium.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 11
- Study locations
NCT04305691: Recruiting Phase 2 study of Kaposi Sarcoma and Skin, sponsored by AIDS Malignancy Consortium.
NCT04305691 is a Phase 2 study of Kaposi Sarcoma and Skin that is actively recruiting participants, run by AIDS Malignancy Consortium. The registered enrollment target is 41 participants, below the 99-participant average among 13 other Kaposi Sarcoma trials with a reported enrollment target (59% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04305691, a Phase 2 study of Kaposi Sarcoma and Skin, is actively recruiting participants, sponsored by AIDS Malignancy Consortium.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 11
- Study locations
Study Summary
This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
The binomial proportion and its 90% one-sided confidence interval will be used to estimate the overall response rate. Response and progression will be evaluated in this study using the acquired Immunodeficiency syndrome (AIDS) Clinical Trials Groups (ACTG) response criteria for Kaposi sarcoma, as outlined in the AIDS Malignancy Consortium (AMC) Kaposi sarcoma Response Evaluation Manual of Procedures (MOP).
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- DRUG Ixazomib Citrate
Study Locations (11)
California
- UC San Diego - San Diego
- Zuckerberg San Francisco General Hospital - San Francisco
Texas
- Thomas Street Clinic - Houston
- Thomas Street Clinic - Houston
Florida
- University of Miami Miller School of Medicine - Miami
Illinois
- University of Illinois Cancer Center - Chicago
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Missouri
- Washington University - St Louis
New York
- Mount Sinai Hospital - New York
Pennsylvania
- Abramson Cancer Center at Pennsylvania Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2029-03-15 |
| Phase | Phase 2 |
What NCT04305691 shows while recruiting
NCT04305691 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 99-participant average among 13 other Kaposi Sarcoma trials with a reported enrollment target (59% lower).
The record links to 2 conditions, with Kaposi Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04305691 lists 11 locations in 9 states (California, Texas, Florida).
Frequently Asked Questions
What is clinical trial NCT04305691 about?
NCT04305691 is a clinical study titled "Trial of Ixazomib for Kaposi Sarcoma". This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT04305691?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2023-11-07. Estimated completion is 2029-03-15.
What conditions does trial NCT04305691 study?
This clinical trial studies the following conditions: Kaposi Sarcoma, Skin.
What interventions are being tested in trial NCT04305691?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Ixazomib Citrate (DRUG).
Who is sponsoring clinical trial NCT04305691?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04305691 being conducted?
This trial has 11 study locations across California, Florida, Illinois, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kaposi Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04305691's enrollment target sits among peer trials
41 11th of 13 higher than 3 of 13 other Kaposi Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kaposi Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
RECRUITING · Phase 2
-
A Study of sEphB4-HSA in Kaposi Sarcoma
RECRUITING · Phase 2
-
Propranolol for the Treatment of Kaposi Sarcoma in Adults
RECRUITING · Phase 2
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
RECRUITING · Phase 1
-
PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI